Status: Recruiting
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.
Participants needed: 75
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Oncorena ABUpdated: May 22, 2026Locations: 5
Eligibility criteria
Has provided written informed consent. [+16]
Diagnosis of any other malignancy within 2 years prior to enrolment, except for... [+8]